DiaMedica Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From DiaMedica Therapeutics Inc.
Public Company Edition: Moderna's $604m IPO launches as the US stock market is in decline and public biotechs are doing especially poorly. Also, as Shire acquisition closing moves near, Takeda firms up additional financing; and Global Blood, Theravance, Amarin capitalize on good news.
Not every drug developer can go public, but biopharma IPOs are launching in multiple markets, including Moderna's prospective $500m US offering and Innovent's $421m Hong Kong IPO. Also, Sarepta prices a $500m FOPO and Omeros sells $210m in notes.
With partner CCHN, Alvotech will help finance construction of a biologics facility in Changchun, China. Novartis will work with Cellular Biomedicine to produce Kymriah for China, and will gain access to its CAR-T platform.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
- In Vitro Diagnostics
- Large Molecule
- Other Names / Subsidiaries
- Sanomune Inc.
- DiaMedica Inc.